ALX Oncology Holdings (ALXO) fair value: what the stock is really worth
As of Oct 14, 2026: fair value of ALX Oncology Holdings $0.11, price $0.89, upside -87.6%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 11, 2026.
How to read this chart
60‑month range $0.4060 – $80.91 · fair‑value band $0.0680 – $0.1360 · the $0.8947 price screens above the $0.1105 fair value. Dashed = 300-day average. As of Oct 11, 2026.
Follow ALX Oncology in your weekly email
Every Wednesday you see whether ALX Oncology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
Show more
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Stock analysis
ALX Oncology Holdings (ALXO) currently trades at $0.8947, while our model-based Fair Value estimate is $0.1105, 87.6% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.0680 (bear) to $0.1360 (bull), the price of $0.8947 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
ALX Oncology Holdings reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$102M in FY2025.
Key figures
Market cap $173M · EPS (TTM) $−1.20 · Return on equity −80.7% · Return on assets (EBIT) −81.3% · Free cash flow −$84.4M · Net cash $11.2M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades about 66% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −88%, ALXO screens richer than that median.
Fair Value models
Bear$0.0680Fair Value $0.1105Bull$0.1360
Price $0.8947 · Upside -87.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−88.7% · Bottom 25%
Profitability
Return on assets−172.2% · Bottom 25%
Operating margin (12 months)0.0% · Above median
Balance sheet
Debt / equity0.17× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B6.65× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)91· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is ALX Oncology Holdings (ALXO) overvalued or undervalued?
As of Oct 11, 2026, our model estimates a fair value of $0.1105 versus a price of $0.8947, about −88% upside (overvalued).
What is the fair value of ALXO?
Our model-based fair value for ALX Oncology Holdings is $0.1105 (as of Oct 11, 2026), built from audited fundamentals. The current price: $0.8947.
What is the quality score of ALXO?
ALX Oncology Holdings has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ALX Oncology Holdings (ALXO)?
Our model-based price target is the fair value of $0.1105 (as of Oct 11, 2026) from 1 valuation models. Cautious scenario $0.0680, optimistic scenario $0.1360. It is a calculation from audited fundamentals, not an analyst target.
What is the ALX Oncology Holdings stock forecast for 2026?
Our models put fair value at $0.1105, about −88% upside versus a price of $0.8947 (overvalued). Cautious scenario $0.0680, optimistic scenario $0.1360. The calculation is refreshed regularly with new filings.
What is the intrinsic value of ALX Oncology Holdings (ALXO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ALX Oncology Holdings it is $0.1105 per share (as of Oct 11, 2026), against a price of $0.8947. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ALX Oncology Holdings stock overvalued or undervalued in 2026?
As of Oct 11, 2026, ALXO trades above its calculated fair value: price $0.8947, fair value $0.1105, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALXO?
No. The price is what the market pays today ($0.8947); the fair value is what the company's own numbers justify ($0.1105). For ALX Oncology Holdings the two are $0.7842 per share apart. That gap is exactly why we show both numbers side by side.
How much is ALX Oncology Holdings worth?
The market values ALX Oncology Holdings at about $173M (market capitalisation, as of Oct 11, 2026). Per share that is $0.8947; our models calculate a fair value of $0.1105 per share.
What do the bullish and bearish scenarios say about ALXO?
Our models span a range for ALX Oncology Holdings: cautious scenario $0.0680, base $0.1105, optimistic $0.1360 per share (as of Oct 11, 2026, price $0.8947). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ALX Oncology Holdings (ALXO)?
Balance-sheet figures for ALX Oncology Holdings (as of Oct 11, 2026): return on equity −80.7%, debt of 0.17 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is ALXO from its 52-week high?
ALX Oncology Holdings trades at $0.8947, about 66% below its 52-week high of $2.60 and at the low of $0.8947 (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1105 is for.
Which stocks are comparable to ALX Oncology Holdings?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ALX Oncology Holdings stock attractive at the current price?
The data as of Oct 11, 2026: price $0.8947, calculated fair value $0.1105 (−88%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALXO calculated?
We run ALX Oncology Holdings through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1105, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. ALX Oncology Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ALX Oncology Holdings (ALXO)?
The closing price on Oct 14, 2026 was $0.8947. Our model-based fair value is $0.1105, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ALX Oncology Holdings right now?
The price sits above even our optimistic bull case ($0.1360). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.0680 to $0.1360) leaves room in how you read the outcome.
Key figures of ALX Oncology Holdings
How large is the market capitalisation of ALX Oncology Holdings (ALXO)?
The market capitalisation of ALX Oncology Holdings is $173M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of ALX Oncology Holdings (ALXO)?
Earnings per share at ALX Oncology Holdings are $−1.20. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of ALX Oncology Holdings (ALXO)?
The return on equity (ROE) of ALX Oncology Holdings is −80.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ALX Oncology Holdings (ALXO)?
On an EBIT basis the return on assets of ALX Oncology Holdings is −81.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does ALX Oncology Holdings (ALXO) generate?
The free cash flow of ALX Oncology Holdings is −$84.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ALX Oncology Holdings (ALXO) hold?
ALX Oncology Holdings holds more cash than debt, $11.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch ALX Oncology Holdings in the live analysis
One click puts ALX Oncology Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 11, 2026